

SCOHIA PHARMA and Huadong Announce Global Expansion of the Strategic Collaboration for SCO-094

Fujisawa, Japan, and Hangzhou, China, February 2nd, 2023 – SCOHIA PHARMA, Inc, a Japanese biotech company, and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd.(SZ.000963), today announced an global expansion of the strategic allaince for SCO-094, a GLP-1R and GIPR dual agonist.

SCOHIA PHARMA and Huadong Medicine entered into a strategic alliance for SCO-094 in 25 countries in the Asia Pacific region excluding Japan in 2021. Under the terms of the new agreement, SCOHIA PHARMA and Huadong Medicine expand the territory from the APAC countries (exlucing Japan) to the worldwide countries (including Japan) and Huadong Meidicine will exclusively develop, manufacture and commercialize SCO-094 and its deravtives throughout the world.

“We are excited to expand our collaboration with Huadong Medicine to include the worldwide countries. This is one of the important milestones for our successful collaboration with Huadong Medicine and to deliver SCO-094 to the patients throughout the world.” stated Masanori Watanabe, President, CEO and CSO of SCOHIA PHARMA. “We are confident that Huadong Medicine’s commitment to the innovation will accelerate development of SCO-094”

“ Huadong Medicine has been continuously strengthening its presence and innovative pipeline in metabolism area. This world-wide collaboration for developing the GLP-1/GIP dual agonist for diabetes, obesity, NASH adds another exciting asset in Huadong’s metabolism portfolio. We are pleased to continue our cooperation with SCOHIA PHARMA, and committed to develop more potentials around the dual agonist for global patients with better treatment option. Stated Dongzhou Jeffery Liu, CSO of Huadong Medicine.

About SCO-094:

SCO-094 is a GLP-1R/GIPR dual agonist that leads to HbA1c and body weight reductions by selectively stimulating both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Strong receptor binding and ex-vivo activities have been shown in preclinical studies. In animal model, it demonstrates potent efficacy of HbA1c reduction, liver function improvement, triglyceride reduction and liver fat inhibition. Preclinical data support its clinical studies of diabetes, obesity, NASH and other metabolic indications. SCO-094 is currently in Phase 1 study in UK.

About Huadong Medicine:

Huadong Medicine Co., Ltd. (SZ.000963) is a leading Chinese pharmaceutical company based in Hangzhou, China. Founded in 1993, Huadong Medicine has fully integrated R&D, manufacturing, distribution, sales and marketing capabilities. Huadong Medicine’s product portfolio and pipeline are specialized in oncology, immunology, nephrology and diabetes. The Company’s annual revenue in 2021 exceeded 5 billion USD. Huadong Medicine has 11,000



employees, and one of the most extensive commercial coverage and marketing capabilities in China. 'Patient Centered, Science Driven' is Huadong's value. For additional information, please visit www.eastchinapharm.com/en.

About SCOHIA PHARMA, Inc.:

SCOHIA PHARMA, Inc. is a drug discovery bioventure focusing on the field of lifestyle-related diseases with high unmet medical needs such as cardiovascular, metabolic, and renal diseases. Our R&D team has a rich pipeline and track record in each stage of drug development, including compound discovery, drug evaluation, and clinical development, which makes us unique. For detailed information about SCOHIA PHARMA, Inc., please visit <https://www.scohia.com/eng/>.

Investor Relations and Media

Huadong Medicine:

Bo Chen

+86 571 8990 3290

pretor@eastchinapharm.com

SCOHIA PHARMA:

Corporate Communications

info@scohia.com